The treatment of steroid-induced bone loss in transplantation

Research output: Contribution to journalReview article

19 Scopus citations

Abstract

Osteopenia after transplantation is a significant cause of morbidity. Despite the lack of randomized, placebo-controlled trials in renal transplantation, there is literature supporting both the prevention and treatment of existing corticosteroid-induced osteoporosis with antiresorptive agents, such as calcitonin and bisphosphonates. The newer pharmacologic agents, nasal spray calcitonin and alendronate, have shown promising results in postmenopausal osteoporosis, and their ease of administration and low incidence of side effects make them ideal for renal transplant patients.

Original languageEnglish (US)
Pages (from-to)544-549
Number of pages6
JournalCurrent Opinion in Nephrology and Hypertension
Volume6
Issue number6
DOIs
StatePublished - Jan 1 1997

    Fingerprint

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology

Cite this